NCT06950190
Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)
Enrolling by Invitation
PHASE3Ages 18+InterventionalEllis MedicineInvestigator-initiated
~100 participants
Updated 2025-08-12 on ClinicalTrials.gov
What's tested:Low-Intensity Walking InterventionControl Group Intervention
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Cognitive Function as Measured by MoCA Score
Measured over Baseline, 6 months, 9 months, and 12 months
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Tallat Mahmood, MD · PRINCIPAL_INVESTIGATOR · Ellis Medicine/ Roswell Park
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
• Age 18 years and older.
Patients with histologically confirmed malignancy who are planning on receiving chemotherapy.
Able and willing to provide written informed consent.
ECOG performance status less than or equal to 2.
Patients willing and able to perform the exercise as directed.
Patients with the ability to walk without use of an assistive device.
Patients with no underlying psychiatric disorder (other than depression, as long as there has been no acute presentation within 6 months of being enrolled in the study).
Exclusion
• Under the age of 18 years.
Patients unable to provide informed consent.
Patients who are non-ambulatory or who have a physical disability preventing exercise.
ECOG performance status greater than 2.
Patients with a psychiatric diagnosis (other than depression)
Patients with a diagnosis of dementia of any type.
Patients with a neurologic disorder that one could reasonably assume to have an underlying cognitive impairment.
Patients with a history of traumatic brain injury.
Patients who will be on chemotherapy for longer than 6 months
What this trial measures
- Change in Cognitive Function as Measured by MoCA ScoreBaseline, 6 months, 9 months, and 12 months
This outcome evaluates whether cognitive decline associated with chemotherapy ("chemo brain") can be measured using the MoCA, a brief and validated tool suitable for clinical settings. The goal is to determine if MoCA can effectively detect changes in cognitive performance over the course of chemotherapy without the need for extensive neuropsychological testing.